Sandoz Settled Generic Drug Price-Fixing Allegations
Pennsylvania businesses should review historical generic drug procurement for potential compensation eligibility.
Updated on Oct. 2, 2026 in Healthcare
Live Poll
Should pharmaceutical companies face financial penalties for manipulating generic drug prices?
Pennsylvania Attorney General Dave Sunday filed for preliminary approval of a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. to resolve allegations of generic drug price manipulation.
Why it matters
The settlement addresses claims that the firms conspired to inflate drug prices and stifle competition between 2009 and 2019, potentially impacting pharmacy and healthcare facility operating costs during that decade.
The $400 million settlement includes a $14.8 million recovery earmarked for Pennsylvania. Eligible consumers and entities who purchased specific generic drugs between May 2009 and December 2019 may qualify for compensation.
The players
Dave Sunday
The Attorney General of Pennsylvania who is leading the state's legal action to secure settlement funds.
Sandoz Inc.
A major pharmaceutical firm specializing in the development and manufacturing of generic and biosimilar medicines.
Fougera Pharmaceuticals Inc.
A pharmaceutical company and affiliate of Sandoz focused on the production of generic topical products.
The details
The settlement follows allegations that Sandoz and its affiliate, Fougera, engaged in conspiracies to artificially fix drug prices. As part of the resolution, Sandoz has committed to internal compliance reforms designed to prevent future antitrust violations. Business operators who managed drug procurement during the decade-long period of alleged price manipulation should assess their past invoices for qualifying purchases.
Timeline
May 2009 marked the start of the period for eligible drug purchases.
December 2019 marked the end of the period for eligible drug purchases.
October 2026 saw the motion for settlement approval filed.
Market Landscape
This $400 million settlement follows an established pattern of state and federal antitrust litigation targeting generic drug pricing. It marks a significant enforcement effort to correct historical market distortions in the pharmaceutical supply chain.
Business operators and procurement managers should determine if their organization purchased generic drugs between 2009 and 2019 to evaluate eligibility. Consult with your organization's legal counsel to assess potential participation in the claims process.
The takeaway
This settlement highlights the long-term reach of antitrust investigations into procurement practices. Managers should track claims windows and maintain detailed purchasing records to capitalize on potential recoveries from historical price-fixing cases.
Further reading
For broader updates on state-level medical industry regulation, visit /business/industry/healthcare/.
More information
To review claim eligibility or submit documentation, visit the Settlement eligibility and claims portal.
Source note: This article includes information reported by WHP.
Live Poll
Should pharmaceutical companies face financial penalties for manipulating generic drug prices?
